PFE News 30.75 04/28/2014 05:54:19 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 30.75 $PFE

AstraZeneca shares soar on Pfizer interest
By DANICA KIRKA - AP - 23 mins ago
LONDON (AP) — Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15 percent on Monday after U.S. pharmaceutical firm Pfizer said it offered to buy the company for around $100 billion.

European Stocks Rise; AstraZeneca Jumps on Renewed Pfizer Interest
at The Street - 27 mins ago
Growing tensions in Ukraine cast a pall over Europe and Asia on Monday but the pharmaceuticals industry delivers more strong medicine and markets in Europe are recovering.

Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - 2 hrs 50 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory

Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Business Wire - Mon Apr 28, 1:08AM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Should These 3 Stingy Stocks Pay Higher Dividends?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Apr 27, 10:35AM CDT
The S&P 500 is a fruitful place to look for stocks that pay solid dividends. But even when a stock has an attractive dividend yield, one question you should always ask is whether that dividend is sustainable. Sometimes, you'll find that a high...

Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...

What Formula Brings Success for This Infant Formula Maker?
Mark Lin, The Motley Fool - Motley Fool - Sat Apr 26, 10:00AM CDT
Source: Mead Johnson While there are many publicly traded food & beverage companies, few can match the stellar financial track record of infant nutrition company Mead Johnson Nutrition . It has been profitable in every single year of the...

IBD 50: Actavis, Spirit Lead 5 Top Earnings On Tap
at Investor's Business Daily - Sat Apr 26, 7:02AM CDT
The market is in correction with tensions in Ukraine weighing on sentiment, but several top-rated companies are slated to report earnings this week. Most of these stocks are holding up relatively well. Spirit Airlines (SAVE), ranked No. 2 on the IBD...

Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...

FDA reviews psychiatric side effects of Chantix
By MATTHEW PERRONE - AP - Fri Apr 25, 4:35PM CDT
WASHINGTON (AP) — The Food and Drug Administration announced Friday it will hold a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.

Teva's Copaxone: Perspectives From a Patient and Investor
Anders Bylund, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
I was diagnosed with multiple sclerosis five years ago. My neurologist asked me to choose one of the classic CRAB (Copaxone, Rebif, Avonex, or Betaseron) therapies, and I settled on Teva Pharmaceutical Industries ' blockbuster Copaxone treatment....

3 Questions About a Big Pharma Megamerger
Seth Robey, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
It's been hard to miss the action in Big Pharma this week, as some of the most established drug makers engaged in a series of acquisition, merger, and asset swap rumors. A buyout of English company AstraZeneca by American powerhouse Pfizer was...

Why This Huge Dividend Stock Has Snoozed Through 2014
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
Pfizer 's one of big pharma's most recognizable names, and this Dow Jones member's recognized as one of the tried-and-true dividend giants among the market's blue-chip health-care stocks. Yet this company's had to fight back the patent cliff's...

Midday Glance: Pharmaceuticals companies
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Early Glance: Pharmaceuticals companies
AP - Fri Apr 25, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.

This Is Dividend Stock Johnson & Johnson’s Major Weakness
Peter Stephens, The Motley Fool - Motley Fool - Fri Apr 25, 8:30AM CDT
In a previous article on  J&J   , I highlighted the company's major strengths -- and it has many, not least of which is its 2.7% dividend yield. Now it's time to focus on its major weakness. Diversity: A double-edged sword While J&J's...

Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.

Pfizer to pay USD0.26 dividend for Q2 2014
M2 - Fri Apr 25, 5:09AM CDT
The board of directors of Pfizer (NYSE FE), a science company, on Thursday declared a dividend of USD0.26 on the company's common stock for its second quarter 2014.

Drugmakers' Q1 was anemic
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Citing R&D and marketing costs, AstraZeneca (AZN) missed EPS estimates with a 17% drop to $1.17. Flat sales of $6.4 bil did beat views. Eli Lilly (LLY) met EPS views of 70 cents, but sales fell 16% to $4.7 bil. Novartis (NVS) EPS slid 3% to $1.28,...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading